Every year, the Medicine Maker, a global publication with a focus on the people that drive the development of small and large molecule drugs as well as advanced therapies, compiles a list of pioneers and influencers advancing the knowledge frontier, driving clinical application, and fostering industry growth. The annual Medicine Maker Power List is compiled
Scientists from Boston Children’s Hospital and Massachusetts Institute of Technology (MIT) have used alpaca-derived nanobodies to create a novel approach to CAR T cell therapy that addresses the challenge of treating patients with solid tumor cancers. Currently, CAR-T cell immunotherapy has been applied to the treatment of non-solid tumors such as acute lymphoblastic leukemia (ALL).
The preservation of biological samples is critical to the success of experimental studies and clinical treatments in the emergent field of immunotherapy. Cryopreservation – keeping cells at sub-zero temperatures – slows metabolic activity significantly, enabling storage and transportation, as well as a return to functionality upon thaw. Of course, it’s not as simple as placing
The development of immunotherapy is one of the greatest advances in cancer treatment, but up to 40% of cancer patients on immune checkpoint inhibitors develop clinically significant immune-related adverse events (irAEs) and up to 80% of individuals receiving checkpoint inhibitors experience some form of irAE. Predicting which patients will react negatively in response to immunotherapy
Cancer can exploit immune regulatory checkpoints molecules by inhibiting anti-tumor immune responses from T cells. These immune checkpoint inhibitor (ICI) antibodies that activate anti-tumor immune responses can create durable responses in 10%–20% of cancer patients, but the remaining 80%–90% of the patients do not respond, driving the need to find novel combination therapies that increase
Cancer therapies utilizing antibodies to disrupt the PD-1/PD-L1 interaction have been among the most exciting developments in immunotherapy with Dr. James Allison and Dr. Tasuku Honjo receiving the Nobel Prize in Medicine this past week for their discovery of cancer therapy by inhibition of negative immune regulation. This premise of this approach to cancer therapy
Chimeric antigen receptor T cell (CAR T) therapies have proved remarkably effective against leukemia and lymphoma, but for these therapies to target other types of cancer, there are still hurdles to overcome. Brain cancer is particularly challenging for immunotherapies due to the blood-brain barrier. This semi-permeable barrier tightly regulates the homeostasis of the central nervous
Chimeric antigen receptors (CARs) significantly enhance the anti-tumor activity of immune effector cells. Current CAR-based immunotherapies leverage engineered versions of a patient’s own T-cells to target and kill cancer cells. Recently, a study led by researchers at University of California San Diego School of Medicine and University of Minnesota demonstrated that similarly modified CAR constructs
T cells expressing chimeric antigen receptors (CAR T) are particularly promising for the treatment of refractory cancers. While Kymriah and Yescarta are FDA-approved for B-cell malignancies, safety and efficacy concerns remain across the cell therapy industry. Severe cytokine release syndrome triggered by T cell infusion is one of the urgent CAR T related downsides that needs
Patients with relapsed or refractory chronic lymphocytic leukemia (CLL) have terrible prognoses and novel cell therapies provide a glimmer of hope. While the CAR T therapy known as Kymriah led to complete remission in over 90% of patients with advanced acute lymphoblastic leukemia (ALL), only 26% of CLL patients responded to it in clinical trials.